Does A subclinical cardiotoxic effect of clozapine exist? Results from a follow-up pilot study

Carlo Rostagno, Sandro Domenichetti, Gian Franco Gensini

Research output: Contribution to journalArticle

Abstract

Aim: The aim of the present study was to investigate by serial echocardiography and dosage of NT-pro-BNP, whether, in previously healthy subjects, long term therapy with clozapine may lead to subclinical cardiac toxicity. Methods and Results: 38 patients (24 males, 14 females, mean age 38.4 years) suffering from a severe personality disorder were enrolled. At inclusion duration of clozapine treatment averaged 66 months at a mean daily dose of 296 mg. Clinical evaluation, NT-pro-BNP dosage and echocardiography were performed at baseline, 3 and 12 months. At first visit 15 patients showed depression of left ventricular function (12 had LVEF between 50 and 55%, 22= -0.4619, p 5% was found in 33% of patients with baseline normal LVEF while LVEF remained below 55% in 70% of group B patients. LVEF and NT-pro-BNP values were still significantly different in the two groups at the term of follow-up. Conclusions: subclinical heart dysfunction, frequently biventricular, occurs in 1/3 of young, previously healthy, clozapine treated patients. NT-pro-BNP values relate inversely with LVEF. At 1 year follow -up a LVEF decrease >5% occurred in 1/3 of patients with baseline normal left ventricular function.

Original languageEnglish
Pages (from-to)148-153
Number of pages6
JournalCardiovascular and Hematological Agents in Medicinal Chemistry
Volume10
Issue number2
Publication statusPublished - Jun 2012

Fingerprint

Clozapine
Left Ventricular Function
Echocardiography
Personality Disorders
Healthy Volunteers
pro-brain natriuretic peptide (1-76)
Therapeutics

Keywords

  • Adverse effects
  • Cardiomyopathy
  • Clozapine
  • Diastolic function
  • Echocardiography
  • Metabolic syndrome
  • NT-pro-BNP
  • QT i nterval
  • Refractory schizophrenia
  • Right ventricular function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology

Cite this

Does A subclinical cardiotoxic effect of clozapine exist? Results from a follow-up pilot study. / Rostagno, Carlo; Domenichetti, Sandro; Gensini, Gian Franco.

In: Cardiovascular and Hematological Agents in Medicinal Chemistry, Vol. 10, No. 2, 06.2012, p. 148-153.

Research output: Contribution to journalArticle

Rostagno, Carlo ; Domenichetti, Sandro ; Gensini, Gian Franco. / Does A subclinical cardiotoxic effect of clozapine exist? Results from a follow-up pilot study. In: Cardiovascular and Hematological Agents in Medicinal Chemistry. 2012 ; Vol. 10, No. 2. pp. 148-153.
@article{c555a35cf896481085cbec8f31bc84a9,
title = "Does A subclinical cardiotoxic effect of clozapine exist? Results from a follow-up pilot study",
abstract = "Aim: The aim of the present study was to investigate by serial echocardiography and dosage of NT-pro-BNP, whether, in previously healthy subjects, long term therapy with clozapine may lead to subclinical cardiac toxicity. Methods and Results: 38 patients (24 males, 14 females, mean age 38.4 years) suffering from a severe personality disorder were enrolled. At inclusion duration of clozapine treatment averaged 66 months at a mean daily dose of 296 mg. Clinical evaluation, NT-pro-BNP dosage and echocardiography were performed at baseline, 3 and 12 months. At first visit 15 patients showed depression of left ventricular function (12 had LVEF between 50 and 55{\%}, 22= -0.4619, p 5{\%} was found in 33{\%} of patients with baseline normal LVEF while LVEF remained below 55{\%} in 70{\%} of group B patients. LVEF and NT-pro-BNP values were still significantly different in the two groups at the term of follow-up. Conclusions: subclinical heart dysfunction, frequently biventricular, occurs in 1/3 of young, previously healthy, clozapine treated patients. NT-pro-BNP values relate inversely with LVEF. At 1 year follow -up a LVEF decrease >5{\%} occurred in 1/3 of patients with baseline normal left ventricular function.",
keywords = "Adverse effects, Cardiomyopathy, Clozapine, Diastolic function, Echocardiography, Metabolic syndrome, NT-pro-BNP, QT i nterval, Refractory schizophrenia, Right ventricular function",
author = "Carlo Rostagno and Sandro Domenichetti and Gensini, {Gian Franco}",
year = "2012",
month = "6",
language = "English",
volume = "10",
pages = "148--153",
journal = "Cardiovascular and Hematological Agents in Medicinal Chemistry",
issn = "1871-5257",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Does A subclinical cardiotoxic effect of clozapine exist? Results from a follow-up pilot study

AU - Rostagno, Carlo

AU - Domenichetti, Sandro

AU - Gensini, Gian Franco

PY - 2012/6

Y1 - 2012/6

N2 - Aim: The aim of the present study was to investigate by serial echocardiography and dosage of NT-pro-BNP, whether, in previously healthy subjects, long term therapy with clozapine may lead to subclinical cardiac toxicity. Methods and Results: 38 patients (24 males, 14 females, mean age 38.4 years) suffering from a severe personality disorder were enrolled. At inclusion duration of clozapine treatment averaged 66 months at a mean daily dose of 296 mg. Clinical evaluation, NT-pro-BNP dosage and echocardiography were performed at baseline, 3 and 12 months. At first visit 15 patients showed depression of left ventricular function (12 had LVEF between 50 and 55%, 22= -0.4619, p 5% was found in 33% of patients with baseline normal LVEF while LVEF remained below 55% in 70% of group B patients. LVEF and NT-pro-BNP values were still significantly different in the two groups at the term of follow-up. Conclusions: subclinical heart dysfunction, frequently biventricular, occurs in 1/3 of young, previously healthy, clozapine treated patients. NT-pro-BNP values relate inversely with LVEF. At 1 year follow -up a LVEF decrease >5% occurred in 1/3 of patients with baseline normal left ventricular function.

AB - Aim: The aim of the present study was to investigate by serial echocardiography and dosage of NT-pro-BNP, whether, in previously healthy subjects, long term therapy with clozapine may lead to subclinical cardiac toxicity. Methods and Results: 38 patients (24 males, 14 females, mean age 38.4 years) suffering from a severe personality disorder were enrolled. At inclusion duration of clozapine treatment averaged 66 months at a mean daily dose of 296 mg. Clinical evaluation, NT-pro-BNP dosage and echocardiography were performed at baseline, 3 and 12 months. At first visit 15 patients showed depression of left ventricular function (12 had LVEF between 50 and 55%, 22= -0.4619, p 5% was found in 33% of patients with baseline normal LVEF while LVEF remained below 55% in 70% of group B patients. LVEF and NT-pro-BNP values were still significantly different in the two groups at the term of follow-up. Conclusions: subclinical heart dysfunction, frequently biventricular, occurs in 1/3 of young, previously healthy, clozapine treated patients. NT-pro-BNP values relate inversely with LVEF. At 1 year follow -up a LVEF decrease >5% occurred in 1/3 of patients with baseline normal left ventricular function.

KW - Adverse effects

KW - Cardiomyopathy

KW - Clozapine

KW - Diastolic function

KW - Echocardiography

KW - Metabolic syndrome

KW - NT-pro-BNP

KW - QT i nterval

KW - Refractory schizophrenia

KW - Right ventricular function

UR - http://www.scopus.com/inward/record.url?scp=84860480382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860480382&partnerID=8YFLogxK

M3 - Article

C2 - 22352685

AN - SCOPUS:84860480382

VL - 10

SP - 148

EP - 153

JO - Cardiovascular and Hematological Agents in Medicinal Chemistry

JF - Cardiovascular and Hematological Agents in Medicinal Chemistry

SN - 1871-5257

IS - 2

ER -